H.C. Wainwright analyst Brandon Folkes lowered the price target on Omeros Corporation to $33 from $40 while maintaining a Buy rating, following a negative CHMP opinion for Yartemlea. The analyst described the opinion as disappointing but not thesis-breaking, and views the U.S. launch of Yartemlea as a key value driver. The price target reduction reflects removal of the EU opportunity from the firm's model and higher R&D spending guidance. Omeros Corporation delivered a one-year return of 200.32% compared to the S&P 500's 20.17%, and its upside potential is approximately 374%.
Omeros CorporationNegative CHMP opinion for Yartemlea removes EU opportunity
Arcutis Biotherapeutics Inc